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ABSTRACT
Objective To assess the cost- effectiveness of 
management strategies for patients presenting with 
chest pain and suspected coronary heart disease (CHD): 
(1) cardiovascular magnetic resonance (CMR); (2) 
myocardial perfusion scintigraphy (MPS); and (3) UK 
National Institute for Health and Care Excellence (NICE) 
guideline- guided care.
Methods Using UK data for 1202 patients from the 
Clinical Evaluation of Magnetic Resonance Imaging 
in Coronary Heart Disease 2 trial, we conducted an 
economic evaluation to assess the cost- effectiveness of 
CMR, MPS and NICE guidelines. Health outcomes were 
expressed as quality- adjusted life- years (QALYs), and 
costs reflected UK pound sterling in 2016–2017. Cost- 
effectiveness results were presented as incremental cost- 
effectiveness ratios and incremental net health benefits 
overall and for low, medium and high pretest likelihood 
of CHD subgroups.
Results CMR had the highest estimated QALY 
gain overall (2.21 (95% credible interval 2.15, 2.26) 
compared with 2.07 (1.92, 2.20) for NICE and 2.11 
(2.01, 2.22) for MPS) and incurred comparable costs 
(overall £1625 (£1431, £1824) compared with £1753 
(£1473, £2032) for NICE and £1768 (£1572, £1989) 
for MPS). Overall, CMR was the cost- effective strategy, 
being the dominant strategy (more effective, less costly) 
with incremental net health benefits per patient of 0.146 
QALYs (−0.18, 0.406) compared with NICE guidelines 
at a cost- effectiveness threshold of £15 000 per QALY 
(93% probability of cost- effectiveness). Results were 
similar in the pretest likelihood subgroups.
Conclusions CMR- guided care is cost- effective overall 
and across all pretest likelihood subgroups, compared 
with MPS and NICE guidelines.
INTRODUCTION
Coronary heart disease (CHD) is a leading cause 
of morbidity and mortality worldwide. In patients 
presenting with chest pain, a range of invasive and 
non- invasive tests are available for the diagnosis 
of CHD and are used to identify patients suitable 
for revascularisation. While myocardial perfusion 
scintigraphy (MPS) is the most commonly used 
non- invasive functional imaging test worldwide, 
cardiovascular magnetic resonance (CMR) has been 
shown to have higher diagnostic accuracy and prog-
nostic value.1 2 Despite the widespread availability 
of non- invasive imaging, invasive coronary angiog-
raphy (ICA) remains frequently used in the diag-
nostic pathway for stable angina, despite its higher 
cost and associated risks. US and UK studies have 
shown that after ICA, a large proportion of patients 
with stable chest pain are found not to have signifi-
cant obstructive disease,3 4 suggesting that ICA may 
be unnecessary and potentially avoidable in many.
The optimal initial investigation strategy in 
patients with stable chest pain remains keenly 
debated, and the cost- effectiveness of different strat-
egies is also unclear. These are likely to depend on 
the pretest likelihood of having CHD.5–7 Updated 
UK clinical guidelines for the diagnosis of stable 
chest pain recommended the use of CT- guided 
care, but used non- standard approaches for cost- 
effectiveness evaluation.8 9 Furthermore, the cost- 
effectiveness of CT- guided management remains 
uncertain.10
The Clinical Evaluation of Magnetic Reso-
nance Imaging in Coronary Heart Disease 2 
(CE- MARC 2) trial compared three diagnostic 
strategies in patients presenting with stable chest 
pain and suspected CHD. The aim of this protocol- 
defined, prespecified analysis was to use data from 
CE- MARC 2 trial to assess the cost- effectiveness, 
from a UK National Health Service (NHS) perspec-
tive, of CMR, MPS and a risk- stratified approach 
based on the UK National Institute for Health and 
Care Excellence (NICE) guidelines (CG95, 2010) at 
the time of the trial.
METHODS
Patient and public involvement
Patients and public advisors (1) were involved in 
the trial design and funding application, (2) were 
members of the trial steering committee and (3) 
oversaw the drafting of all patient- facing materials.
Study design
The economic evaluation compared alternative 
diagnostic strategies in terms of their health effects 
based on quality- adjusted life- years (QALYs) and 
their costs from a UK NHS perspective over 36 
months based on trial follow- up. Key data were 
taken from CE- MARC 2, the full details of which 
have been published.11 12 Briefly, CE- MARC 2 was a 
UK multicentre, three- arm, randomised controlled 
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30 years or older with a 10%–90% pretest likelihood of CHD 
and considered suitable for coronary revascularisation.11 12 The 
trial compared three management strategies: (1) CMR- guided 
care, (2) MPS- guided care and (3) UK NICE guidelines (CG95, 
2010).13 Patients randomised to NICE guidelines care were 
stratified according to their pretest likelihood: those with a 
10%–29% (low) pretest likelihood were scheduled for cardiac 
CT (CCT); those with a 30%–60% (medium) pretest likelihood 
were scheduled for MPS; and those with a 61%–90% (high) 
pretest likelihood were sent directly to ICA. A positive scan 
(CMR, MPS, CCT) resulted in protocol- defined ICA and frac-
tional flow reserve measurement. In this study, 1202 patients 
were randomised 2:2:1 to CMR, MPS and NICE guidelines 
guided care, respectively. Figure 1 illustrates the study flow 
diagram and investigative strategies. The study was conducted 
in accordance with the protocol which was approved by the UK 
National Research Ethics Service (12/YH/0404) and institutional 
review boards of participating centres. Informed written consent 
was obtained from all participants.
Resource use and costs
Data on diagnostic and revascularisation- related resource use 
were collected using individual case record forms. Data relating 
to outpatient visits, inpatient hospitalisation and cardiovascular 
medication were collected at annual follow- up.
Costs reflected unit costs in pound sterling at 2016–2017 
prices,14–16 and were grouped into diagnostic costs, revascu-
larisation costs (percutaneous coronary intervention (PCI) 
or coronary artery bypass grafting (CABG)), inpatient costs 
(cardiovascular- related hospitalisations), outpatient costs, drug 
costs and total costs. To reduce the risk of spurious cost differ-
ences resulting from random imbalance in the revascularisation 
procedures administered in each trial arm (CABG or PCI), a 
weighted average revascularisation cost was applied.
Costs for the diagnostic procedures were based on NHS refer-
ence costs.14 Scenario analyses considered revised MPS unit costs 
(which do not account for costing the stress and rest procedures 
separately) and tariff prices (hospital reimbursement rates).17 
Unit costs for the diagnostic tests and revascularisations are 
shown in table 1. Other unit costs are shown in online supple-
mentary tables S1 and S2.
Outcomes
Health outcomes were expressed as QALY, a generic measure of 
health capturing survival and health- related quality of life. These 
were estimated based on patients’ responses to the EQ- 5D- 3L 
questionnaire at baseline and at 6, 12, 24 and 36 months 
postrandomisation.18 The EQ- 5D- 3L asks patients to rate their 
health (no problems, moderate problems or severe problems) 
in the following categories: mobility, self- care, usual activity, 
pain/discomfort and anxiety/depression. When combined, these 
ratings define health states that have been assigned values based 
on the preferences of a representative sample of the UK popu-
lation.19 The EQ- 5D scores and survival data were combined 
to estimate QALYs using the area under the curve method with 
linear interpolation between time points.20 As an alternative 
scenario, the EQ- 5D- 5L questionnaire and its associated values 
were used.21 22
Analysis
The analysis assessed both an overall comparison of the trial arms 
and a stratified analysis for each pretest likelihood stratum (low, 
medium, high), since previous research indicates the expected 
prognostic value of a diagnostic strategy is dependent on pretest 
likelihood.5–7 Costs and QALYs were discounted at 3.5% per 
annum.9 Where data items were missing, multiple imputation 
was used to estimate costs by category, and EQ- 5D- 3L and 
EQ- 5D- 5L scores.23
Unadjusted resource use, costs by resource category, total 
costs and QALYs are presented. Cost- effectiveness results were 
Figure 1 CE- MARC 2 study flow diagram illustrating randomisation and investigative strategies. CE- MARC 2, Clinical Evaluation of Magnetic 
Resonance Imaging in Coronary Heart Disease 2; CMR, cardiovascular magnetic resonance; LV, left ventricular; ICA, invasive coronary angiography; 
MPS, myocardial perfusion scintigraphy; NICE, National Institute for Health and Care Excellence; PTL, pretest likelihood; CCT, cardiac computed 
tomography.





Cardiovascular magnetic resonance £393.71
Myocardial perfusion scintigraphy £588.94
Invasive coronary angiography £1068.47
Revascularisation procedures
Percutaneous coronary intervention £3124.81
Coronary artery bypass grafting £11 046.22
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based on an adjusted analysis, controlling for a set of patient 
covariables and for potential imbalances in the number of revas-
cularisations across arms. Patient covariables were selected based 
on multivariable p<0.1 and considered diabetes, family history 
of CHD, baseline ECG result, trial centre, body mass index, 
smoking status plus baseline EQ- 5D in the QALY regression.24
Costs and QALYs were estimated within trial arm and pretest 
likelihood group conditional on whether a revascularisation was 
undertaken or not. Results are then calculated as the weighted 
average of revascularised and non- revascularised patients 
using common revascularisation rates within pretest likelihood 
groups. This assumes that any differences in revascularisation 
rates between trial arms reflect sampling error. Generalised 
linear models were used for the cost analysis, accounting for the 
non- normality and skewed nature of cost data.25 For QALYs an 
ordinary least squares regression was applied.
Results are presented in terms of mean costs and QALYs with 
95% credible intervals. Incremental cost- effectiveness ratios 
(ICERs) were calculated, which report the incremental cost 
per QALY gained of one strategy compared with the next less 
effective and less costly strategy. A strategy was excluded from 
ICER calculations if it were strictly or extendedly dominated, 
that is, more costly and less effective or more costly per addi-
tional QALY than the next more effective strategy, respectively. 
Incremental net health benefits per patient of each strategy 
compared with NICE- guided care were also estimated, which 
capture the overall health gain from one individual receiving the 
care. This measure reflects any health benefits to that individual 
from the strategy plus/minus the impact on other individuals’ 
health from any change in resource requirements. If a strategy is 
cost- saving those resources can be used to improve the health of 
other patients, resulting in further health gain, while if it is more 
costly those resources are not available for others, resulting in 
health loss. Incremental net health benefits were estimated based 
on three measures of the QALYs that could have been generated 
elsewhere in the NHS from the same resources (health oppor-
tunity cost): £15 000 per QALY based on the Department of 
Health and Social Care’s chosen threshold,26 and £20 000 and 
£30 000 per QALY reflecting the range used by NICE.9
Uncertainty in these estimates and the probability of each 
strategy being the most costly, most effective and cost- effective 
(for each health opportunity cost) were estimated using Monte 
Table 2 Estimated mean costs and QALYs per patient (unadjusted)
CMR (n=481) MPS (n=481) NICE (n=240)
LPTL MPTL HPTL Overall LPTL MPTL HPTL Overall LPTL MPTL HPTL Overall
Mean costs* n=128 n=179 n=174 n=481 n=125 n=183 n=173 n=481 n=61 n=88 n=91 n=240


































































































Mean QALYs* n=128 n=179 n=174 n=481 n=125 n=183 n=173 n=481 n=61 n=88 n=91 n=240
































































































*Discounted at 3.5% rate per annum
†Other costs comprise cardiovascular- related inpatient, outpatient and drug- related costs.
CMR, cardiovascular magnetic resonance; HPTL, high pretest likelihood; LPTL, low pretest likelihood; MPS, myocardial perfusion scintigraphy; MPTL, medium pretest likelihood; NICE, National Institute for Health and 
Care Excellence guidance; QALY, quality- adjusted life- years.
Figure 2 Proportion of patients who underwent diagnostic and revascularisation procedures. Non- invasive diagnostic is defined as any MPS, CMR, 
cardiac CT, exercise tolerance test, echocardiogram or stress echocardiogram. Revascularisation is defined by any percutaneous coronary intervention 
or coronary artery bypass grafting. CMR, cardiovascular magnetic resonance; MPS, myocardial perfusion scintigraphy; NICE, National Institute for 








































































































4 Walker S, et al. Heart 2020;0:1–8. doi:10.1136/heartjnl-2020-316990
Coronary artery disease
Carlo simulation. A number of scenario analyses were consid-
ered, including (1) not controlling for differential revasculari-
sation rates across arms; (2) NHS tariff diagnostic costs; (3) 
diagnostic costs only; (4) revised MPS unit cost; (5) EQ- 5D- 5L 
scores; and (6) a pooled functional imaging strategy (CMR and 
MPS). Finally, we examined the unit cost of CMR at which it is 
no longer cost- effective.
RESULTS
Resource use, costs and health outcomes
The average age of patients in the trial was 56.3 years, 46.9% of 
patients were women, and 26.1% were of low, 37.4% were of 
medium and 36.4% were of high pretest likelihood.12 Missing 
data were low for resource use but higher for EQ- 5D scores. 
Table 2 presents unadjusted diagnostic, revascularisation and 
total costs, along with annual and total QALYs. Figure 2 pres-
ents the proportion of patients who underwent diagnostic and 
Table 3 Base- case cost- effectiveness results
Mean cost per patient Mean QALY per patient
ICER
Incremental mean net health benefit per patient* (95% CI)
(95% CI) (95% CI) k=£15 000 k=£20 000 k=£30 000
(P (most costly)) (P (most effective)) (probability of being cost- effective)
Low PTL
NICE £787.92 2.20095   – – –
  (531.64 to 1046.85) (2.05635 to 2.36087) – – –
  (0.047) (0.130) (0.160) (0.153) (0.147)
CMR £846.00 2.28702 £674.83 0.082 0.083 0.084
  (597.5 to 1098.28) (2.19106 to 2.38562) (−0.096 to 0.257) (−0.093 to 0.258) (−0.091 to 0.259)
  (0.083) (0.719) (0.736) (0.729) (0.722)
MPS £1061.94 2.22261 Dominated 0.003 0.008 0.013
  (835.89 to 1293.69) (2.13167 to 2.3122) (−0.173 to 0.171) (−0.166 to 0.173) (−0.161 to 0.177)
  (0.870) (0.151) (0.104) (0.118) (0.131)
Medium PTL
CMR £1301.97 2.19738   0.220 0.216 0.211
  (1056.23 to 1560.61) (2.09621 to 2.29582) (0.047 to 0.398) (0.041 to 0.393) (0.036 to 0.388)
  (0.074) (0.642) (0.688) (0.682) (0.671)
MPS £1391.20 2.17327 Dominated 0.19 0.187 0.184
  (1105.68 to 1684.8) (2.0717 to 2.26984) (0.023 to 0.36) (0.021 to 0.355) (0.018 to 0.355)
  (0.211) (0.353) (0.310) (0.316) (0.326)
NICE £1565.28 1.99474 Dominated – – –
  (1114.65 to 1991.53) (1.85789 to 2.12644) – – –
  (0.715) (0.005) (0.002) (0.002) (0.003)
High PTL
CMR £2514.86 2.15591   0.115 0.113 0.111
  (2058.12 to 2936.73) (2.06893 to 2.24084)   (−0.18 to 0.406) (−0.185 to 0.401) (−0.186 to 0.395)
  (0.184) (0.747)   (0.758) (0.755) (0.750)
NICE £2638.37 2.04944 Dominated – – –
  (2048.84 to 3213.82) (1.78434 to 2.3057) – – –
  (0.400) (0.213) (0.204) (0.207) (0.211)
MPS £2660.93 1.97525 Dominated −0.076 −0.075 −0.075
  (2154.92 to 3139.48) (1.76637 to 2.18188) (−0.368 to 0.213) (−0.361 to 0.212) (−0.358 to 0.213)
  (0.416) (0.040) (0.038) (0.038) (0.039)
Overall
CMR £1624.82 2.20568   0.146 0.144 0.141
  (1431.4 to 1824.44) (2.14564 to 2.26468)   (−0.013 to 0.306) (−0.013 to 0.302) (−0.013 to 0.302)
  (0.073) (0.917)   (0.931) (0.926) (0.925)
NICE £1753.24 2.06854 Dominated – – –
  (1473.15 to 2031.75) (1.92352 to 2.20276) – – –
  (0.440) (0.035) (0.029) (0.032) (0.031)
MPS £1767.87 2.11400 Dominated 0.044 0.045 0.045
  (1571.78 to 1989.15) (2.01256 to 2.2169) (−0.103 to 0.189) (−0.101 to 0.187) (−0.1 to 0.187)
  (0.487) (0.048) (0.040) (0.042) (0.044)
P (most costly): probability of a strategy being the most costly alternative.
P (most effective): probability of a strategy being the most effective alternative (ie, highest QALY gain).
*All incremental net health benefits are estimated compared with NICE- guided care.
CI, credible intervals; CMR, cardiovascular magnetic resonance; ICER, incremental cost- effectiveness ratio; k, cost- effectiveness threshold; MPS, myocardial perfusion scintigraphy; 
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revascularisation procedures. Online supplementary tables S3–
S6 report further costs, resource use and EQ- 5D scores.
Overall, patients in the NICE arm were most likely to have 
received ICA (43.8%). Revascularisation rates were comparable 
but highest in the CMR arm (11.4%). Total costs were similar 
between the arms (£1695–£1735), with CMR’s lower diagnostic 
costs offset by higher revascularisation costs. Mean QALYs were 
lowest in the NICE arm and highest in the CMR arm.
In low pretest likelihood patients, a higher proportion in the 
NICE arm underwent ICA (11.5%) than in the CMR (5.5%) 
and MPS (6.4%) arms, and only a small proportion of patients 
received a revascularisation procedure (1.6%–2.3%). The MPS 
arm had the highest total mean cost at £1038, compared with 
£862 and £757 in the CMR and NICE arms, respectively. Mean 
QALYs were lowest in the NICE arm and highest in the CMR 
arm.
For medium pretest likelihood patients, similar propor-
tions of patients underwent ICA (15.1%–15.9%) across the 
trial arms, although revascularisations were lowest for MPS. 
Revascularisation costs were lowest for the MPS arm, while 
diagnostic costs were highest for the NICE arm. NICE arm 
had the highest total mean cost at £1657, while CMR (£1351) 
and MPS (£1347) incurred comparable costs. Mean QALYs 
were similar between CMR and MPS, but markedly lower in 
the NICE arm.
In high pretest likelihood patients, the NICE arm had the 
highest proportion of patients receiving ICA (92.3%), although 
this was below the 100% protocol for NICE guidelines. Revascu-
larisation rates and mean total costs were highest for CMR, with 
a mean cost totalling £2741, compared with £2538 and £2465 
in the MPS and NICE arms, respectively. Mean QALYs were 
highest in the CMR arm, although similar across the trial arms.
Cost-effectiveness
Table 3 presents the adjusted base- case mean costs, QALYs 
and cost- effectiveness results for each trial arm overall and by 
pretest likelihood stratum. Figure 3 presents the results on cost- 
effectiveness planes. Online supplementary figure S1 presents 
the cost- effectiveness acceptability curves.
Overall, CMR was found to be the least costly and most effec-
tive strategy, with a 7% probability of being most costly and 
a 92% probability of the highest QALY gain. The mean incre-
mental net health benefit per patient of CMR compared with 
NICE ranged from 0.141 to 0.146 QALYs across the health 
opportunity cost estimates considered, and the probability 
of CMR being cost- effective is over 93% for each. However, 
there is considerable uncertainty with the 95% credible intervals 
across all three arms overlapping for mean costs and QALYs.
In low pretest likelihood patients, the NICE arm was the least 
costly and least effective strategy. CMR was the second most 
costly and the most effective, with an ICER of £675 per QALY 
and a mean incremental net health benefit ranging from 0.082 
to 0.084 QALYs per patient. The probability of CMR being cost- 
effective exceeded 72% for each health opportunity cost esti-
mate considered.
For medium pretest likelihood patients, the CMR arm was 
the least costly and most effective strategy, while NICE was the 
least effective and most costly option. CMR had a mean incre-
mental net health benefit ranging from 0.211 to 0.220 QALYs 
per patient, with the probability of CMR being cost- effective 
exceeding 67% for each health opportunity cost estimate 
considered.
For high pretest likelihood patients, the CMR arm was the 
least costly and most effective strategy, whereas MPS was the 
least effective and most costly option, and NICE the second 
Figure 3 Base- case cost- effectiveness plane. CMR, cardiovascular magnetic resonance; ICER, incremental cost- effectiveness ratio; MPS, myocardial 
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most costly and the second most effective. CMR had mean incre-
mental net health benefit ranging from 0.111 to 0.115 QALYs 
per patient, with the probability of CMR being cost- effective 
exceeding 75% for each health opportunity cost estimate 
considered.
Scenario analysis
Table 4 presents the cost- effectiveness results for the scenario 
analyses. Online supplementary tables S7–S13 present the 
detailed breakdown of these results.
When not controlling for differential revascularisation rates 
across arms, conclusions remain unchanged, although with 
results comparably less favourable for CMR.
When using tariff- based diagnostic unit costs, CMR became 
most costly overall and for the low and medium pretest likeli-
hood groups. Overall and for each pretest likelihood stratum, 
CMR had positive incremental net health benefits and ICERs 
below the health opportunity cost estimates considered.
Considering diagnostic costs only made the cost differentials 
more favourable for CMR overall and for each pretest likelihood 
stratum.
With revised MPS costs, MPS becomes the least costly arm 
overall and for the medium and high pretest likelihood strata. 
Overall and for each pretest likelihood stratum, CMR had posi-
tive incremental net health benefits and ICERs below the health 
opportunity cost estimates considered.
Table 4 Scenario analyses: cost- effectiveness results








Not controlling for differential revascularisation rates NHS tariffs
Low PTL NICE £739.72 2.20158   Low PTL NICE £727.67 2.20095   
CMR £890.25 2.27686 £1999.70 MPS £791.10 2.22261 Dominated
MPS £1066.30 2.22813 Dominated CMR £875.51 2.28702 £1310.57
Medium PTL CMR £1314.13 2.21530   Medium PTL MPS £1135.14 2.17327   
MPS £1322.85 2.23666 Dominated NICE £1309.26 1.99474 Dominated
NICE £1619.41 2.05109 Dominated CMR £1311.50 2.19738 £7317.38
High PTL NICE £2484.19 2.17658   High PTL MPS £2347.23 1.97525   
MPS £2504.96 2.14166 Dominated CMR £2532.14 2.15591 £1023.51
CMR £2728.52 2.19613 £12 495.02 NICE £2604.59 2.04944 Dominated
Overall MPS £1686.59 2.19981   Overall MPS £1486.94 2.11400   
NICE £1704.73 2.13613 Dominated NICE £1629.34 2.06854 Dominated
CMR £1718.79 2.22440 £1309.99 CMR £1642.40 2.20568 £1695.61
Diagnostic costs only Revised MPS unit costs
Low PTL NICE £430.21 2.20095   Low PTL NICE £775.50 2.20095   
CMR £458.95 2.28702 £333.92 MPS £806.95 2.22261 Extendedly 
dominated
MPS £695.64 2.22261 Dominated CMR £844.72 2.28702 £586.35
Medium PTL CMR £581.88 2.19738   Medium PTL MPS £1143.37 2.17327   
MPS £768.27 2.17327 Dominated CMR £1308.54 2.19738 £6853.24
NICE £821.61 1.99474 Dominated NICE £1313.72 1.99474 Dominated
High PTL CMR £827.45 2.15591   High PTL MPS £2398.76 1.97525   
MPS £988.42 1.97525 Dominated CMR £2511.51 2.15591 £768.46
NICE £1 1123.81 2.04944 Dominated NICE £2621.23 2.04944 Dominated
Overall CMR £639.25 2.20568   Overall MPS £1512.94 2.11400   
NICE £829.48 2.06854 Dominated CMR £1625.73 2.20568 £1230.20
MPS £829.52 2.11400 Dominated NICE £1649.57 2.06854 Dominated
EQ-5D- 5L   PFIA
Low PTL NICE £787.92 2.43234   Low PTL NICE £794.34 2.15534   
CMR £846.00 2.47754 £1285.02 PFIA £963.27 2.25924 £1625.92
MPS £1061.94 2.45839 Dominated   
Medium PTL CMR £1301.97 2.41772   Medium PTL PFIA £1344.22 2.20270   
MPS £1391.20 2.40701 Dominated NICE £1563.73 2.02996 Dominated
NICE £1565.28 2.30330 Dominated   
High PTL CMR £2514.86 2.36506   High PTL PFIA £2579.61 2.13792   
NICE £2638.37 2.26125 Dominated NICE £2617.76 2.14353 £6800.50
MPS £2660.93 2.31846 Dominated   
Overall CMR £1624.82 2.41415   Overall PFIA £1695.81 2.19386   
NICE £1753.24 2.32169 Dominated NICE £1747.78 2.10410 Dominated
MPS £1767.87 2.38816 Dominated   
The full results for each scenario are reported in online supplementary tables S7–S12.
CMR, cardiovascular magnetic resonance; ICER, incremental cost- effectiveness ratio; MPS, myocardial perfusion scintigraphy; NHS, National Health Service; NICE, National 
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Using EQ- 5D- 5L scores to estimate QALYs did not have a 
marked impact on the cost- effectiveness results, with conclusions 
remaining unchanged. For all patients, QALYs are notably higher 
with EQ- 5D- 5L, reflecting differences between the EQ- 5D- 3L 
and EQ- 5D- 5L value sets.
The pooled functional imaging arm was found to be more effec-
tive overall and in the low and medium pretest likelihood strata, 
and less costly in the medium and high pretest likelihood strata. 
Pooled functional imaging was found to be cost- effective overall 
(dominant) and for low pretest likelihood (ICER of £1626 per 
QALY) and medium pretest likelihood patients (dominant). For 
high pretest likelihood patients, NICE was more expensive and 
more effective with an ICER of £6801 per QALY (cost- effective 
at health opportunity cost estimates considered).
Finally, we considered what the cost of CMR would have to be 
for the CMR to not be cost- effective at the different health oppor-
tunity costs (online supplementary table S13). The costs would 
have to be markedly higher than the £394 unit cost (minimum 
£938, maximum £4129) for CMR not to be cost- effective.
DISCUSSION
This study has estimated the resource use, costs and cost- 
effectiveness of diagnostic strategies for patients with suspected 
CHD based on the CE- MARC 2 trial. Controlling for revascu-
larisation status and patients’ baseline characteristics, CMR was 
determined to be the most effective and cost- effective strategy 
overall and for all pretest likelihood subgroups. The results 
remained robust across alternative scenarios, despite the differ-
ences in costs and outcomes being highly uncertain.
These findings need to be interpreted with caution. Results 
are potentially driven by random baseline imbalances between 
the arms, where smaller numbers of patients, with potentially 
different baseline prognoses and care requirements, inform 
each strategy and pretest likelihood stratum. The potential 
impact of random baseline imbalances is demonstrated with the 
MPS and NICE arms being equivalent strategies in the medium 
pretest likelihood group (ie, both strategies scheduling MPS 
as an initial test), but the latter incurring more costs (£174) 
and associated with less QALYs (−0.1785). Furthermore, not 
controlling for differential revascularisation rates across trial 
arms provides less favourable results for CMR due to what may 
have been random imbalances in patients requiring revascular-
isation. Expanding the analysis to consider more types of costs 
does incorporate potentially relevant observed differentials 
in resource use, but also increases the potential for random 
imbalances impacting results. Nonetheless, our conclusions 
remained robust when considering only the costs of the diag-
nostic procedures.
The current findings suggest that CMR directed care is 
cost- effective and has a high prognostic value relative to MPS 
and NICE guidelines directed care. These findings support 
a previous analysis of the CE- MARC study,5 but conflict with 
those of Genders et al,6 who found that CCT was likely to be 
cost- effective in low- risk patients, a strategy akin to the NICE 
guidelines arm, which was the least effective arm in low pretest 
likelihood patients and deemed not cost- effective. Our results 
inform a knowledge gap relating to the cost- effectiveness of 
CCT- guided management. The results of the SCOT- HEART 
trial have informed an update of the NICE CG95 guidelines.8 10 
However, in SCOT- HEART, compared with standard care, the 
CCT strategy was associated with more angina and worse quality 
of life.27 A health economic analysis of the SCOT- HEART trial 
has not been reported.
This study has a number of strengths and weaknesses. The 
analysis is based on a large and pragmatic diagnostic strategy 
study which has the potential to demonstrate the impact of each 
strategy on patients’ costs and outcomes. By controlling for 
patient covariables and the impact of revascularisation status, 
attempts have been made to address what may be considered 
baseline imbalances. However, there are a number of weak-
nesses. First, it is difficult for diagnostics to influence down-
stream costs and benefits, other than through their impact on 
treatment decisions, and whether long- term differences in 
observed costs and outcomes in the trial are attributable to the 
alternative diagnostic strategies is uncertain. Second, estimating 
results conditional on revascularisation status generates more 
imprecise estimates, particularly in the low pretest likelihood 
group where revascularisation was rarely performed. Third, 
we have not considered the implications beyond 3 years, for 
example, any subsequent impacts on mortality or morbidity or 
the impact of ionising radiation on cancer incidence. Fourth, we 
have only considered the strategies included in the CE- MARC 
2 trial and this excluded other potentially relevant compara-
tors which may be cost- effective.6 8 Fifth, while recent trials 
such as ISCHEMIA may suggest diagnostic imaging could be 
used more judiciously, with ageing populations and increasing 
multimorbidity it is likely overall rates of imaging will continue 
to increase.28 Sixth, the analysis has been undertaken from the 
NHS perspective and only considers costs and benefits relevant 
to the NHS; a broader ‘societal’ perspective may consider other 
impacts such as productivity and environmental costs.29 Lastly, 
the potential for random baseline imbalances remains, while the 
results themselves are highly uncertain.
In conclusion, this study has estimated the costs and cost- 
effectiveness of diagnostic strategies. The results suggest CMR 
is cost- effective overall and across pretest likelihood subgroups, 
compared with MPS and NICE guidelines- guided care.
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Key messages
What is already known on this subject?
 ► The optimal strategy for the diagnosis of patients with 
suspected coronary heart disease is a source of much debate.
 ► Despite the availability of non- invasive imaging, invasive 
coronary angiography remains frequently used despite its 
higher cost and associated risks.
What might this study add?
 ► This study estimated the resource use, costs and cost- 
effectiveness of different diagnostic strategies for patients 
with suspected coronary heart disease based on the Clinical 
Evaluation of Magnetic Resonance Imaging in Coronary Heart 
Disease 2 trial.
 ► Cardiovascular magnetic resonance- guided care was 
determined to be the most effective and cost- effective 
strategy overall and for all pretest likelihood subgroups.
 ► The results remained robust across various alternative 
scenarios, despite the differences in costs and outcomes 
between each strategy being highly uncertain.
How might this impact on clinical practice?
 ► The findings of this study support the expanded use of 
cardiovascular magnetic resonance- guided care in the 
diagnosis of patients with suspected coronary heart disease.
 ► The study suggests that this can improve health outcomes 
while lowering costs.
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